Literature DB >> 26192934

Patient Selection for Drip and Ship Thrombolysis in Acute Ischemic Stroke.

Michael J Lyerly1, Karen C Albright1, Amelia K Boehme1, Reza Bavarsad Shahripour1, John P Donnelly1, James T Houston1, Pawan V Rawal1, Niren Kapoor1, Muhammad Alvi1, April Sisson1, Anne W Alexandrov1, Andrei V Alexandrov1.   

Abstract

OBJECTIVES: The drip and ship model is a method used to deliver thrombolysis to acute stroke patients in facilities lacking onsite neurology coverage. We sought to determine whether our drip and ship population differs from patients treated directly at our stroke center (direct presenters).
METHODS: We retrospectively reviewed consecutive patients who received thrombolysis at an outside facility with subsequent transfer to our center between 2009 and 2011. Patients received thrombolysis after telephone consultation with a stroke specialist. We examined demographics, vascular risk factors, laboratory values, and stroke severity in drip and ship patients compared with direct presenters.
RESULTS: Ninety-six patients were identified who received thrombolysis by drip and ship compared with 212 direct presenters. The two groups did not differ with respect to sex, ethnicity, vascular risk factors, or admission glucose. The odds ratio (OR) of arriving at our hospital as a drip and ship for someone 80 years or older was 0.31 (95% confidence interval [CI] 0.15-0.61, P < 0.001). Only 21% of drip and ship patients were black versus 38% of direct presenters (OR 0.434, 95% CI 0.25-0.76, P = 0.004). Even after stratifying by age (<80 vs ≥80), a smaller proportion of drip and ship patients were black (OR 0.44, 95% CI 0.24-0.81, P = 0.008). Furthermore, we found that fewer black patients with severe strokes arrived by drip and ship (OR 0.33, 95% CI 0.11-0.98, P = 0.0028).
CONCLUSIONS: Our study showed that a smaller proportion of blacks and older adults arrived at our center by the drip and ship model. This may reflect differences in how patients are selected for thrombolysis and transfer to a higher level of care.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26192934      PMCID: PMC5523805          DOI: 10.14423/SMJ.0000000000000306

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  28 in total

1.  Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

Authors:  Opeolu Adeoye; Richard Hornung; Pooja Khatri; Dawn Kleindorfer
Journal:  Stroke       Date:  2011-06-02       Impact factor: 7.914

2.  Why are eligible thrombolysis candidates left untreated?

Authors:  Nancy K Hills; S Claiborne Johnston
Journal:  Am J Prev Med       Date:  2006-11-07       Impact factor: 5.043

3.  Intravenous tissue plasminogen activator and stroke in the elderly.

Authors:  W T Longstreth; Ronit Katz; David L Tirschwell; Mary Cushman; Bruce M Psaty
Journal:  Am J Emerg Med       Date:  2010-03       Impact factor: 2.469

Review 4.  Recommendations for improving the quality of care through stroke centers and systems: an examination of stroke center identification options: multidisciplinary consensus recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association.

Authors:  Robert Adams; Joe Acker; Mark Alberts; Liz Andrews; Richard Atkinson; Kathy Fenelon; Anthony Furlan; Meighan Girgus; Katie Horton; Richard Hughes; Walter Koroshetz; Richard Latchaw; Ellen Magnis; Marc Mayberg; Arthur Pancioli; Rose Marie Robertson; Tim Shephard; Rene Smith; Sidney C Smith; Suzanne Smith; Steven K Stranne; Edgar J Kenton; Gil Bashe; Altagracia Chavez; Larry Goldstein; Richard Hodosh; Cindy Keitel; Margaret Kelly-Hayes; Anne Leonard; Lewis Morgenstern; Jack Owen Wood
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

5.  Is ED disposition associated with intracerebral hemorrhage mortality?

Authors:  Opeolu Adeoye; Mary Haverbusch; Daniel Woo; Padmini Sekar; Charles J Moomaw; Dawn Kleindorfer; Brian Stettler; Brett M Kissela; Joseph P Broderick; Matthew L Flaherty
Journal:  Am J Emerg Med       Date:  2010-03-25       Impact factor: 2.469

6.  Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.

Authors:  Jeffrey L Saver; Banafsheh Yafeh
Journal:  Stroke       Date:  2007-01-18       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?

Authors:  Sheryl Martin-Schild; Miriam M Morales; Aslam M Khaja; Andrew D Barreto; Hen Hallevi; Anitha Abraham; M Rick Sline; Elizabeth Jones; James C Grotta; Sean I Savitz
Journal:  J Emerg Med       Date:  2009-03-09       Impact factor: 1.484

9.  Care seeking after stroke symptoms.

Authors:  Virginia J Howard; Daniel T Lackland; Judith H Lichtman; Leslie A McClure; George Howard; Libby Wagner; Leavonne Pulley; Camilo R Gomez
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

10.  Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989.

Authors:  R D Brown; J P Whisnant; J D Sicks; W M O'Fallon; D O Wiebers
Journal:  Stroke       Date:  1996-03       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.